SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hebert J) "

Sökning: WFRF:(Hebert J)

  • Resultat 31-40 av 114
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  •  
32.
  • Holgate, S. T., et al. (författare)
  • Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
  • 2004
  • Ingår i: Clin Exp Allergy. ; 34:4
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Patients with severe asthma are often inadequately controlled on existing anti-asthma therapy, constituting an unmet clinical need. OBJECTIVE: This randomized, double-blind, placebo-controlled trial evaluated the ability of omalizumab, a humanized monoclonal anti-IgE antibody, to improve disease control sufficiently to enable inhaled corticosteroid reduction in patients with severe allergic asthma. METHODS: After a run-in period when an optimized fluticasone dose (> or =1000 microg/day) was received for 4 weeks, patients were randomized to receive subcutaneous omalizumab [minimum 0.016 mg/kg/IgE (IU/mL) per 4 weeks; n=126] or matching placebo (n=120) at intervals of 2 or 4 weeks. The study comprised a 16-week add-on phase of treatment followed by a 16-week fluticasone-reduction phase. Short-/long-acting beta(2)-agonists were allowed as needed. RESULTS: Median reductions in fluticasone dose were significantly greater with omalizumab than placebo: 60% vs. 50% (P=0.003). Some 73.8% and 50.8% of patients, respectively, achieved a > or =50% dose reduction (P=0.001). Fluticasone dose reduction to < or =500 microg/day occurred in 60.3% of omalizumab recipients vs. 45.8% of placebo-treated patients (P=0.026). Through both phases, omalizumab reduced rescue medication requirements, improved asthma symptoms and asthma-related quality of life compared to placebo. CONCLUSION: Omalizumab treatment improves asthma control in severely allergic asthmatics, reducing inhaled corticosteroid requirements without worsening of symptom control or increase in rescue medication use.
  •  
33.
  • Jonkman, Nini H., et al. (författare)
  • What Are Effective Program Characteristics of Self-Management Interventions in Patients With Heart Failure? : An Individual Patient Data Meta-analysis
  • 2016
  • Ingår i: Journal of Cardiac Failure. - : Elsevier BV. - 1071-9164 .- 1532-8414. ; 22:11, s. 861-871
  • Tidskriftsartikel (refereegranskat)abstract
    • Background To identify those characteristics of self-management interventions in patients with heart failure (HF) that are effective in influencing health-related quality of life, mortality, and hospitalizations.Methods and Results Randomized trials on self-management interventions conducted between January 1985 and June 2013 were identified and individual patient data were requested for meta-analysis. Generalized mixed effects models and Cox proportional hazard models including frailty terms were used to assess the relation between characteristics of interventions and health-related outcomes. Twenty randomized trials (5624 patients) were included. Longer intervention duration reduced mortality risk (hazard ratio 0.99, 95% confidence interval [CI] 0.97–0.999 per month increase in duration), risk of HF-related hospitalization (hazard ratio 0.98, 95% CI 0.96–0.99), and HF-related hospitalization at 6 months (risk ratio 0.96, 95% CI 0.92–0.995). Although results were not consistent across outcomes, interventions comprising standardized training of interventionists, peer contact, log keeping, or goal-setting skills appeared less effective than interventions without these characteristics.Conclusion No specific program characteristics were consistently associated with better effects of self-management interventions, but longer duration seemed to improve the effect of self-management interventions on several outcomes. Future research using factorial trial designs and process evaluations is needed to understand the working mechanism of specific program characteristics of self-management interventions in HF patients.
  •  
34.
  • Trillo-Muyo, Sergio, 1983, et al. (författare)
  • Granule-stored MUC5B mucins are packed by the non-covalent formation of N-terminal head-to-head tetramers
  • 2018
  • Ingår i: Journal of Biological Chemistry. - : American Society for Biochemistry and Molecular Biology. - 0021-9258 .- 1083-351X. ; 293:15, s. 5746-5754
  • Tidskriftsartikel (refereegranskat)abstract
    • Most MUC5B mucin polymers in the upper airways of humans and pigs are produced by submucosal glands. MUC5B forms N-terminal covalent dimers that are further packed into larger assemblies because of low pH and high Ca2+ in the secretory granule of the mucin-producing cell. We purified the recombinant MUC5B N-terminal covalent dimer and used single-particle electron microscopy to study its structure under intracellular conditions. We found that, at intragranular pH, the dimeric MUC5B organized into head-to-head noncovalent tetramers where the von Willebrand D1-D2 domains hooked into each other. These N-terminal tetramers further formed long linear complexes from which, we suggest, the mucin domains and their C termini project radially outwards. Using conventional and video microscopy, we observed that, upon secretion into the submucosal gland ducts, a flow of bicarbonate-rich fluid passes the mucin-secreting cells. We suggest that this unfolds and pulls out the MUC5B assemblies into long linear threads. These further assemble into thicker mucin bundles in the glandular ducts before emerging at the gland duct opening. We conclude that the combination of intracellular packing of the MUC5B mucin and the submucosal gland morphology creates an efficient machine for producing linear mucin bundles.
  •  
35.
  • Axen, Iben, et al. (författare)
  • Misinformation, chiropractic, and the COVID-19 pandemic
  • 2020
  • Ingår i: Chiropractic and Manual Therapies. - : BioMed Central (BMC). - 2045-709X. ; 28:1
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Background: In March 2020, the World Health Organization elevated the coronavirus disease (COVID-19) epidemic to a pandemic and called for urgent and aggressive action worldwide. Public health experts have communicated clear and emphatic strategies to prevent the spread of COVID-19. Hygiene rules and social distancing practices have been implemented by entire populations, including 'stay-at-home' orders in many countries. The long-term health and economic consequences of the COVID-19 pandemic are not yet known.Main text: During this time of crisis, some chiropractors made claims on social media that chiropractic treatment can prevent or impact COVID-19. The rationale for these claims is that spinal manipulation can impact the nervous system and thus improve immunity. These beliefs often stem from nineteenth-century chiropractic concepts. We are aware of no clinically relevant scientific evidence to support such statements. We explored the internet and social media to collect examples of misinformation from Europe, North America, Australia and New Zealand regarding the impact of chiropractic treatment on immune function. We discuss the potential harm resulting from these claims and explore the role of chiropractors, teaching institutions, accrediting agencies, and legislative bodies.Conclusions: Members of the chiropractic profession share a collective responsibility to act in the best interests of patients and public health. We hope that all chiropractic stakeholders will view the COVID-19 pandemic as a call to action to eliminate the unethical and potentially dangerous claims made by chiropractors who practise outside the boundaries of scientific evidence.
  •  
36.
  •  
37.
  • Chabris, CF, et al. (författare)
  • Most reported genetic associations with general intelligence are probably false positives
  • 2012
  • Ingår i: Psychological science. - : SAGE Publications. - 1467-9280 .- 0956-7976. ; 23:11, s. 1314-1323
  • Tidskriftsartikel (refereegranskat)abstract
    • General intelligence ( g) and virtually all other behavioral traits are heritable. Associations between g and specific single-nucleotide polymorphisms (SNPs) in several candidate genes involved in brain function have been reported. We sought to replicate published associations between g and 12 specific genetic variants (in the genes DTNBP1, CTSD, DRD2, ANKK1, CHRM2, SSADH, COMT, BDNF, CHRNA4, DISC1, APOE, and SNAP25) using data sets from three independent, well-characterized longitudinal studies with samples of 5,571, 1,759, and 2,441 individuals. Of 32 independent tests across all three data sets, only 1 was nominally significant. By contrast, power analyses showed that we should have expected 10 to 15 significant associations, given reasonable assumptions for genotype effect sizes. For positive controls, we confirmed accepted genetic associations for Alzheimer’s disease and body mass index, and we used SNP-based calculations of genetic relatedness to replicate previous estimates that about half of the variance in g is accounted for by common genetic variation among individuals. We conclude that the molecular genetics of psychology and social science requires approaches that go beyond the examination of candidate genes.
  •  
38.
  • Chauvier, D, et al. (författare)
  • Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor.
  • 2011
  • Ingår i: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 2
  • Tidskriftsartikel (refereegranskat)abstract
    • Brain protection of the newborn remains a challenging priority and represents a totally unmet medical need. Pharmacological inhibition of caspases appears as a promising strategy for neuroprotection. In a translational perspective, we have developed a pentapeptide-based group II caspase inhibitor, TRP601/ORPHA133563, which reaches the brain, and inhibits caspases activation, mitochondrial release of cytochrome c, and apoptosis in vivo. Single administration of TRP601 protects newborn rodent brain against excitotoxicity, hypoxia-ischemia, and perinatal arterial stroke with a 6-h therapeutic time window, and has no adverse effects on physiological parameters. Safety pharmacology investigations, and toxicology studies in rodent and canine neonates, suggest that TRP601 is a lead compound for further drug development to treat ischemic brain damage in human newborns.
  •  
39.
  • Chen, G., et al. (författare)
  • Abilities of the BRICHOS domain to prevent neurotoxicity and fibril formation are dependent on a highly conserved Asp residue
  • 2022
  • Ingår i: RSC Chemical Biology. - : Royal Society of Chemistry (RSC). - 2633-0679. ; 3:11, s. 1342-1358
  • Tidskriftsartikel (refereegranskat)abstract
    • Proteins can self-assemble into amyloid fibrils or amorphous aggregates and thereby cause disease. Molecular chaperones can prevent both these types of protein aggregation, but to what extent the respective mechanisms are overlapping is not fully understood. The BRICHOS domain constitutes a disease-associated chaperone family, with activities against amyloid neurotoxicity, fibril formation, and amorphous protein aggregation. Here, we show that the activities of BRICHOS against amyloid-induced neurotoxicity and fibril formation, respectively, are oppositely dependent on a conserved aspartate residue, while the ability to suppress amorphous protein aggregation is unchanged by Asp to Asn mutations. The Asp is evolutionarily highly conserved in >3000 analysed BRICHOS domains but is replaced by Asn in some BRICHOS families. The conserved Asp in its ionized state promotes structural flexibility and has a pKa value between pH 6.0 and 7.0, suggesting that chaperone effects can be differently affected by physiological pH variations. 
  •  
40.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 114
Typ av publikation
tidskriftsartikel (99)
konferensbidrag (11)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (106)
övrigt vetenskapligt/konstnärligt (8)
Författare/redaktör
Stewart, G. (9)
Hebert, C. (9)
Kanai, Y. (9)
Alexander, SPH (9)
Benson, HE (9)
Faccenda, E (9)
visa fler...
Pawson, AJ (9)
Sharman, JL (9)
Peters, JA (9)
Kelly, E (9)
Marrion, N (9)
Southan, C (9)
Davies, JA (9)
Aldrich, R (9)
Attali, B (9)
Back, M (9)
Barnes, NM (9)
Bathgate, R (9)
Beart, PM (9)
Becirovic, E (9)
Biel, M (9)
Birdsall, NJ (9)
Boison, D (9)
Brauner-Osborne, H (9)
Broer, S (9)
Bryant, C (9)
Burnstock, G (9)
Burris, T (9)
Cain, D (9)
Calo, G (9)
Chan, SL (9)
Chandy, KG (9)
Chiang, N (9)
Christakos, S (9)
Christopoulos, A (9)
Chun, JJ (9)
Chung, JJ (9)
Clapham, DE (9)
Connor, MA (9)
Coons, L (9)
Cox, HM (9)
Dautzenberg, FM (9)
Dent, G (9)
Douglas, SD (9)
Dubocovich, ML (9)
Edwards, DP (9)
Farndale, R (9)
Fong, TM (9)
Forrest, D (9)
Fowler, CJ (9)
visa färre...
Lärosäte
Karolinska Institutet (70)
Kungliga Tekniska Högskolan (39)
Lunds universitet (19)
Göteborgs universitet (16)
Uppsala universitet (15)
Sveriges Lantbruksuniversitet (9)
visa fler...
Linköpings universitet (6)
Mittuniversitetet (6)
Umeå universitet (5)
Stockholms universitet (4)
Linnéuniversitetet (4)
Karlstads universitet (3)
Luleå tekniska universitet (2)
Jönköping University (2)
Handelshögskolan i Stockholm (2)
Södertörns högskola (2)
Örebro universitet (1)
Högskolan Dalarna (1)
Naturhistoriska riksmuseet (1)
visa färre...
Språk
Engelska (114)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (37)
Medicin och hälsovetenskap (33)
Teknik (3)
Samhällsvetenskap (2)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy